PLD Space and D-Orbit sign launch agreement for equatorial missions
The contract ensures continued access to flexible and efficient launch solutions tailored to the evolving needs of satellite operators worldwide.
With this agreement, PLD Space has now fulfilled more than 80% of the slots in its manifest until 2027.
Elche (Spain): PLD Space, an international space services company with vertical integrated engineering and manufacturing, has signed an agreement with D-Orbit, a global leader in space logistics and orbital transportation, to deploy satellites aboard MIURA 5 to equatorial orbit. With this, PLD Space has now fulfilled more than 80% of the slots in its manifest until 2027.
With investment in space accelerating at an unprecedented rate -particularly in Southeast Asia and other geographies situated near the equator- PLD Space and D-Orbit are well positioned to capitalize on this growth. MIURA 5, launching from its strategic site at the CSG (Kourou, French Guiana), provides one of the few dedicated low-inclination launch opportunities available, offering customers direct access to equatorial orbits. This differentiates PLD Space from other major providers, whose standard offerings for many seeking access to space do not include this service. Currently, the niche is primarily served by one or two launch vehicles offering very low cadences, underscoring the importance of PLD Space's entry into this underserved market.
Through this agreement, D-Orbit will fly payloads aboard MIURA 5, including its flagship ION Orbital Transfer Vehicle (OTV). D-Orbit provides logistics services to the space sector, including in-orbit satellite transportation with individual deployment into specific orbital slots, as well as in-space testing of hosted payloads. The company also offers satellite operators in-orbit storage and advanced computing capabilities. As the market leader in in-space logistics, D-Orbit has successfully deployed satellites into precise orbits through 17 ION missions to date. The contract with PLD Space ensures continued access to flexible and efficient launch solutions tailored to the evolving needs of satellite operators worldwide.
'From our launch complex in Kourou, French Guiana, and Duqm, Oman, we offer one of the widest ranges of orbital inclinators providing our customers with a significant competitive advantage,' said Raúl Verdú, CBDO and Co-founder at PLD Space. 'The agreement with D-Orbit strengthens our position as a leader, especially in markets that require reliable equatorial access, a capability that remains extremely limited in today's industry.'
'Working with PLD Space will allow us to expand our launch offering to equatorial missions, an option that is becoming increasingly interesting for our customers, enabling us to better meet their evolving needs while building a promising collaboration with PLD Space,' commented Matteo Lorenzoni, VP Commercial Strategy of D-Orbit.
PLD Space is currently ramping-up the serial production for MIURA 5 units using the flight proven technology coming from MIURA 1, with the aim of starting its test flight campaign by the end of 2025. Commercial flights of MIURA 5 will begin in 2026 with the objective of scaling up to 30 launches per year by 2030.
About PLD Space
PLD Space is an international space services company with its own engineering and manufacturing. It is dedicated to transporting satellites and people to space, vertically integrating the engineering, testing, manufacturing, and operations of its reusable and sustainable rockets. Headquartered in Elche (Spain) and founded in 2011 by Raúl Torres and Raúl Verdú, PLD Space has established itself as a benchmark in the space launcher sector globally. Its MIURA family of launchers and its LINCE manned capsule position the company as a leader in European technological sovereignty in space transport, covering the entire range of space missions.
With a team of more than 300 employees and more than 12,500 m² dedicated to advanced manufacturing, PLD Space manages facilities in Teruel, Kourou (French Guiana) and Duqm (Oman), allowing it to offer complete satellite launch services and other payloads to space.
For more information:
María Climent, Communications Manager at PLD Spacemaria.climent@p
ldspace.comwww.pldspa
ce.com
Burson
equipoburson.pldspace@bcw-global.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
a day ago
- Zawya
SIBUR Develops New Grade of Polypropylene for Hygiene Products
MOSCOW, RUSSIA - Media OutReach Newswire - 30 July 2025 - SIBUR, Russia's largest polymer producer, has developed a new grade of polypropylene designed for use in hygiene and medical products. The company expects to sell over 1,000 tonnes of this polymer grade by the end of 2025. The new product was created by the SIBUR PolyLab research centre and the Nizhnekamskneftekhim plant, in collaboration with the R&D team from a leading Russian manufacturer of hygiene products that supplies nonwoven materials to multinational companies. The new polypropylene grade, PP MG182 K, has proven to be an effective alternative to traditional hygiene solutions that rely on blends of several polymer grades. Its technical properties make it suitable for supply both within Russia and to international markets as a raw material for the production of nonwoven fabrics. Over the past two decades, the use of polypropylene-based nonwovens (spunbond fabrics) in the hygiene and medical sectors has grown considerably. Since consumers value the softness of materials that come into direct contact with the skin, manufacturers have traditionally relied on special additives to enhance the softness of polypropylene spunbond. SIBUR has successfully developed a proprietary polypropylene copolymer that provides the required softness without the use of foreign additives that are no longer available in the Russian market. The development team also aims to further improve the material to eliminate the use of phthalates, additives facing stricter regulation in several countries. This enhancement will broaden the scope of application of the copolymer grade as well as its export potential. Hashtag: #SIBUR The issuer is solely responsible for the content of this announcement. SIBUR
Zawya
3 days ago
- Zawya
Minapharm's majority shareholder Triquera raises capital through minority stake investment from Admaius Capital Partners
Cairo, Egypt - Admaius Capital Partners ('Admaius'), an Africa-focused private equity investor, and Triquera B.V. ('Triquera'), the majority shareholder in Minapharm Pharmaceuticals and Chemical Industries S.A.E. ('Minapharm'), a leading biopharmaceutical company in the Middle East and Africa and a global provider of proprietary technologies to leading biopharma players, today announced a strategic partnership following Admaius' investment in Triquera B.V. For over two decades, Minapharm has established a robust biopharmaceutical platform that combines world-class R&D with end-to-end manufacturing capabilities for complex genetically engineered therapeutic recombinant proteins and viral vectors as well as small molecules with advanced galenic formulations, operating across facilities in Cairo and Berlin. Today, Minapharm operates the largest biological drug substance and drug product facilities in the Middle East and Africa. Through its international subsidiaries, Minapharm licenses out proprietary technologies in the fields of monoclonal antibodies, vaccines, and cell and gene therapies. These technologies enable the development and production of advanced biologics that address critical unmet medical needs globally and have been incorporated into FDA-approved products, underscoring their clinical relevance and global impact. Together, Triquera and Admaius will focus on accelerating the development and production of complex genetically engineered therapies, while expanding access to high-quality, affordable recombinant proteins by investing in innovation and scaling distribution to better serve patients across underserved markets in Africa and the Middle East. In parallel, the partnership will pursue strategic acquisitions of global contract development and manufacturing organizations (CDMOs) to support Minapharm's growth in the biotech sector. This partnership reflects a shared commitment to advancing healthcare equity through innovation and aligns closely with Admaius' broader strategy of supporting mission-driven businesses and management teams in high-impact sectors across the African continent. Zilla Capital acted as the sole financial advisor to Triquera B.V. and the existing shareholders. Matouk Bassiouny served as legal counsel to Triquera B.V. and the existing shareholders. Admaius Capital Partners was advised by White and Case LLP as legal counsel and by Arthur D. Little as commercial advisor. Commenting on the investment: Dr. Wafik Bardissi, Chairman and CEO of Minapharm, said: "This partnership reflects the accelerating momentum of Minapharm's growth as we extend our leadership in biotherapeutics, cell and gene therapies, and proprietary platform technologies. With Admaius, we gain not only capital but a strategic partner whose insight, alignment, and ambition match our own. Together, we are advancing regional self-sufficiency and expanding the global reach of our innovations." Marlon Chigwende, Managing Partner of Admaius, said: 'This is a landmark transaction. The founding families have built a unique asset on the African and European continents that combines scale, growth and impact to fight cancer and other awful diseases. We are pleased to be able to partner with Triquera, Dr. Wafik and Dr. Shaheer and will help to internationalize and grow the business further.' Ahmed Rady, Managing Director of Admaius, said: 'At Admaius, we back exceptional management teams—and the team behind Minapharm is as impressive as the science, technology, and capabilities they've built across Cairo and Berlin. This partnership is about scaling a homegrown champion that combines cutting-edge global know-how with end-to-end manufacturing excellence. We're excited to support Minapharm in taking this next big step and look forward to working closely with the management team.' Dr. Shaheer Bardissi, Co-CEO of Minapharm, added: 'This strategic collaboration with Admaius will accelerate and scale Minapharm's vision of translating cutting-edge scientific innovation into affordable therapies, while advancing global scientific frontiers in immunotherapy as well as advanced therapy medicinal products, for the benefit of the broader biopharmaceutical industry.' Contacts For more information, please contact: Minapharm Christina Azmy cazmy@ (+2) (02) 24143170 Admaius Hannah Gilkes Phone number: +44 7515 958912
Zawya
6 days ago
- Zawya
Ambassador GAO Wenqi Visits Chinese-Invested Enterprises in Rwanda
On July 25, Ambassador GAO Wenqi visited the C&D Products Group. The company executives gave a briefing on the company's production, operations, and development, as well as the working and living conditions of its employees. Ambassador GAO encouraged the company to adhere to safe production and compliant operation, and take good care of its employees, so as to actively fulfill its social responsibilities and set up a good image for Chinese enterprises. He also asked the company to actively take part in and contribute to Rwanda's economic and social development, and promote China-Rwanda relations. Specializing in apparel manufacturing and export, C&D was established in Rwanda in 2019. It has created over 7,000 jobs for local communities. Distributed by APO Group on behalf of Embassy of the People's Republic of China in the Republic of Rwanda.
